Inogen Inc (INGN), a leading medical technology company, is renowned for its breakthrough product line in the field of oxygen therapy. The company is principally engaged in developing, manufacturing, and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients battling chronic respiratory conditions.
Founded in 2001, Inogen made a significant impact in the medical technology sector by developing a pioneering technology that concentrates the oxygen found in room air to supply it for therapeutic purposes. This was a radical shift from the traditional delivery method of providing oxygen through heavy, non-portable equipment.
The primary advantage of Inogen’s systems is portability. The innovative oxygen concentrators they manufacture significantly improve the quality of life of patients who require supplemental oxygen. They’re offered a level of independence and mobility previously unattainable, allowing them to carry on with their day-to-day life with ease.
Inogen offers three core products to meet various needs - the Inogen At Home, the Inogen One G2, and the Inogen One G3. The 'Inogen At Home' is a stationary oxygen concentrator designed for home use. In contrast, the 'Inogen One G2' and the 'Inogen One G3' are lightweight and portable, designed for active users who need access to oxygen therapy while they’re on the move.
Striving beyond manufacturing, Inogen also provides after-sales services, including sales representatives and customer service support. They believe that empowering customers with knowledge about their conditions and potential therapies can improve patients' overall health outcomes.
In their almost two decades of operations, Inogen has established a strong reputation for innovation. The company’s commitment to research and development has resulted in patents that solidify their positioning in the medical technology industry.
With the management’s commitment to ‘breathe new life into product innovation,’ the company continues to enhance the design and performance of their products. They have strived to stay at the forefront of the field by developing more efficient technologies and innovative oxygen delivery platforms.
Inogen’s financial track record has represented stable growth coupled with operational efficiency. It is listed on the NASDAQ under the ticker INGN and operates internationally compared to other respiratory product manufacturers.
Overall, Inogen has forever changed the landscape of respiratory care. Their ongoing research and dedication to innovation reflect their commitment to improving the lives of those requiring supplemental oxygen. Through their remarkable products and services, Inogen engrains its mission of providing freedom and independence to oxygen therapy users globally.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Inogen's recent Q2 2026 financial report showed revenue of US$95.084 million and a reduced net loss, yet investors are down 24.3% over the past year. The article highlights the importance of net margin improvement over just revenue growth for a company whose thesis relies on margin repair. It discusses how the current trading price of US$6.34 reflects a need for product launches and digital health efforts to translate into significantly higher margins.
Inogen reported a 3% year-over-year revenue increase to $95.1 million in Q2 2026, driven by strong international growth and new products, despite a 2% decline in U.S. sales. The company raised its adjusted EBITDA guidance to $4 million for the full year 2026, while lowering its revenue guidance due to U.S. channel mix shifts and international distributor inventory management. Inogen continues to invest in product innovation, particularly with its Voxi and Aurora products, and is advancing regulatory processes in China for long-term growth opportunities.
Inogen has announced a definitive agreement to sell its U.S. oxygen rental business to Rotech Healthcare for an estimated cash consideration of up to $25 million. This divestiture is part of Inogen's strategy to streamline its operations, focusing on respiratory innovation and partnering with HME providers for broader product distribution. The company anticipates improved profitability and growth by concentrating on its core competencies while ensuring continued patient access to its oxygen concentrators through Rotech's network.
Inogen has agreed to sell its US oxygen rental business to Rotech Healthcare for up to $25 million to refine its focus on product innovation. The deal, expected to close by Q4 2026, includes a long-term supply agreement with Rotech to expand access to Inogen's oxygen concentrators. This strategic move follows declining revenues in the rental segment and aims to strengthen Inogen's business and financial profile amidst rising COPD cases.
This article analyzes Inogen Inc (NASDAQ: INGN), noting a near-term neutral sentiment suggesting a pause in its mid and long-term weakness. It highlights an exceptional 75.0:1 risk-reward setup targeting a 15.3% gain against a 0.2% risk, and provides three AI-generated trading strategies for different risk profiles. The strategies include position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss zones.
This article reviews Inogen's portable oxygen concentrators for 2026, focusing on the Inogen Rove 4 and Rove 6 models. It highlights their lightweight design, FAA approval for air travel, battery life, and pulse-dose delivery system, noting that they may not be suitable for those needing continuous-flow oxygen. The review also covers pricing, pros and cons of each model, and customer feedback.